Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles from the last 7 days matching "new treatment"

PolicyRSSToday

FDA Announces Major Steps to Implement Real-Time Clinical Trials

The FDA announced new steps to make clinical trials happen in real-time, meaning doctors can collect and use patient data as it happens instead of waiting until the end of a study. Real-time clinical trials could help researchers test new treatments faster and more efficiently. This is part of a bigger FDA effort to modernize how drug and treatment testing works.

WHY IT MATTERSReal-time clinical trials could speed up how quickly new treatments for rare diseases reach patients by allowing researchers to analyze data continuously rather than waiting months or years for traditional trial completion.
Good to knowRead →
AdvocacyRSS6 days ago

Patient-led group launches network of clinics to improve LGMD care

A patient-led nonprofit called The Speak Foundation has created a network of specialized clinics called LGMD Centers of Excellence to help people with limb-girdle muscular dystrophy (LGMD), a rare muscle disease. This new network aims to solve a major problem: patients with LGMD have had trouble getting consistent care and doctors have struggled to develop new treatments because the patient population is very small and spread out.

WHY IT MATTERSThis coordinated clinic network could help LGMD patients access specialized care in one place and speed up the development of new treatments by making it easier for researchers to find and study patients.
Good to knowLimb-girdle muscular dystrophy (LGMD)Read →
AdvocacyRSS6 days ago

Collaboration aims to improve design of FSHD clinical trials

Three organizations that work with facioscapulohumeral muscular dystrophy (FSHD) patients are joining together to make clinical trials better. FSHD is a rare muscle disease that causes weakness in the face, shoulders, and upper arms. This partnership wants to improve how these trials are designed so they can test new treatments more effectively.

WHY IT MATTERSBetter-designed clinical trials mean faster progress toward treatments for FSHD, and patient input through the FSHD Society ensures trials are structured in ways that actually work for people living with the disease.
Good to knowFacioscapulohumeral muscular dystrophyRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases